Magle Chemoswed Holding
27,4
SEK
Mindre end 1K følgere
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-4,86%
+1,48%
-12,18%
-21,26%
-17,47%
-15,1%
+20,65%
-
+36,36%
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Læs mereMarkedsværdi
562,14 mio. SEK
Aktieomsætning
-
Omsætning
236,04 mio.
EBIT %
9,84 %
P/E
0,62
Udbytteafkast, %
-
Finanskalender
1.8
2025
Delårsrapport Q2'25
31.10
2025
Delårsrapport Q3'25
27.2
2026
Årsrapport '25
Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Magle Chemoswed Holding Reports Financial Results For First Quarter 2025
Magle Chemoswed Holding AB (publ) Releases Annual Report for 2024.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools